TickerStat.comEloxx Pharmaceuticals annual current ratio
2011
2012
2013
2014
2015
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
Eloxx Pharmaceuticals Current Ratio Growth & History (ELOX)
Eloxx Pharmaceuticals's current ratio was 0.31 for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.31 | 0.20 | +181.56% |
| 2024 | 2024-12-31 | 0.11 | 0.04 | +59.77% |
| 2023 | 2023-12-31 | 0.07 | −0.80 | −92.18% |
| 2022 | 2022-12-31 | 0.87 | −3.50 | −80.04% |
| 2021 | 2021-12-31 | 4.37 | 1.74 | +65.95% |
| 2020 | 2020-12-31 | 2.63 | −2.26 | −46.15% |
| 2019 | 2019-12-31 | 4.89 | −1.56 | −24.20% |
| 2018 | 2018-12-31 | 6.45 | −0.71 | −9.93% |
| 2017 · Dec 31 | 2017-12-31 | 7.16 | 5.93 | +483.96% |
| 2017 · Jun 30 | 2017-06-30 | 0.10 | −2.56 | −96.15% |
| 2016 · Dec 31 | 2016-12-31 | 1.23 | −3.50 | −74.04% |
| 2016 · Jun 30 | 2016-06-30 | 2.66 | −2.13 | −44.41% |
| 2015 · Dec 31 | 2015-12-31 | 4.72 | — | — |
| 2015 · Jun 30 | 2015-06-30 | 4.79 | 0.83 | +21.04% |
| 2014 | 2014-06-30 | 3.96 | 2.86 | +261.02% |
| 2013 | 2013-06-30 | 1.10 | −0.03 | −2.30% |
| 2012 | 2012-06-30 | 1.12 | −0.42 | −27.46% |
| 2011 | 2011-06-30 | 1.55 | — | — |
Eloxx Pharmaceuticals quarterly current ratio
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q4.16
Q1.17
Q4.16
Q1.17
Q4.17
Q1.18
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q4.24
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.74 | — | — |
| Q1 2026 | 2026-03-31 | 0.53 | — | — |
| Q4 2025 | 2025-12-31 | 0.31 | 0.20 | +181.56% |
| Q4 2024 | 2024-12-31 | 0.11 | 0.04 | +59.77% |
| Q4 2023 | 2023-12-31 | 0.07 | −0.80 | −92.18% |
| Q3 2023 | 2023-09-30 | 0.24 | −0.94 | −79.74% |
| Q2 2023 | 2023-06-30 | 0.25 | −1.37 | −84.36% |
| Q1 2023 | 2023-03-31 | 0.33 | −1.87 | −85.03% |
| Q4 2022 | 2022-12-31 | 0.87 | −3.50 | −80.04% |
| Q3 2022 | 2022-09-30 | 1.18 | −4.45 | −78.97% |
| Q2 2022 | 2022-06-30 | 1.62 | −2.23 | −57.93% |
| Q1 2022 | 2022-03-31 | 2.20 | 0.63 | +39.78% |
| Q4 2021 | 2021-12-31 | 4.37 | 1.74 | +65.95% |
| Q3 2021 | 2021-09-30 | 5.63 | 2.40 | +74.52% |
| Q2 2021 | 2021-06-30 | 3.85 | 0.23 | +6.42% |
| Q1 2021 | 2021-03-31 | 1.57 | −2.57 | −62.05% |
| Q4 2020 | 2020-12-31 | 2.63 | −2.26 | −46.15% |
| Q3 2020 | 2020-09-30 | 3.23 | −2.73 | −45.82% |
| Q2 2020 | 2020-06-30 | 3.62 | −3.45 | −48.84% |
| Q1 2020 | 2020-03-31 | 4.14 | −2.44 | −37.06% |
| Q4 2019 | 2019-12-31 | 4.89 | −1.56 | −24.20% |
| Q3 2019 | 2019-09-30 | 5.95 | −5.10 | −46.13% |
| Q2 2019 | 2019-06-30 | 7.07 | −7.61 | −51.85% |
| Q1 2019 | 2019-03-31 | 6.58 | 3.25 | +97.46% |
| Q4 2018 | 2018-12-31 | 6.45 | −0.71 | −9.93% |
| Q3 2018 | 2018-09-30 | 11.05 | 10.09 | +1045.56% |
| Q2 2018 | 2018-06-30 | 14.69 | 14.58 | +14222.95% |
| Q1 2018 · Mar 31 | 2018-03-31 | 3.33 | 3.08 | +1194.99% |
| Q4 2017 · Dec 31 | 2017-12-31 | 7.16 | 5.93 | +483.96% |
| Q1 2018 · Sep 30 | 2017-09-30 | 0.96 | 0.16 | +19.93% |
| Q4 2017 · Jun 30 | 2017-06-30 | 0.10 | −2.56 | −96.15% |
| Q1 2017 · Mar 31 | 2017-03-31 | 0.26 | −3.99 | −93.94% |
| Q4 2016 · Dec 31 | 2016-12-31 | 1.23 | −3.50 | −74.04% |
| Q1 2017 · Sep 30 | 2016-09-30 | 0.80 | −4.61 | −85.13% |
| Q4 2016 · Jun 30 | 2016-06-30 | 2.66 | −2.13 | −44.41% |
| Q1 2016 · Mar 31 | 2016-03-31 | 4.25 | 3.89 | +1076.26% |
| Q4 2015 · Dec 31 | 2015-12-31 | 4.72 | 3.79 | +407.17% |
| Q1 2016 · Sep 30 | 2015-09-30 | 5.41 | 3.01 | +125.73% |
| Q4 2015 · Jun 30 | 2015-06-30 | 4.79 | 0.83 | +21.04% |
| Q3 2015 | 2015-03-31 | 0.36 | −6.65 | −94.85% |
| Q2 2015 | 2014-12-31 | 0.93 | −1.39 | −59.85% |
| Q1 2015 | 2014-09-30 | 2.40 | 1.74 | +266.01% |
| Q4 2014 | 2014-06-30 | 3.96 | 2.86 | +261.02% |
| Q3 2014 | 2014-03-31 | 7.01 | 5.99 | +585.06% |
| Q2 2014 | 2013-12-31 | 2.32 | 1.80 | +349.61% |
| Q1 2014 | 2013-09-30 | 0.65 | −0.15 | −18.82% |
| Q4 2013 | 2013-06-30 | 1.10 | −0.03 | −2.30% |
| Q3 2013 | 2013-03-31 | 1.02 | −0.38 | −26.86% |
| Q2 2013 | 2012-12-31 | 0.52 | −0.42 | −44.64% |
| Q1 2013 | 2012-09-30 | 0.81 | −0.42 | −34.33% |
| Q4 2012 | 2012-06-30 | 1.12 | −0.42 | −27.46% |
| Q3 2012 | 2012-03-31 | 1.40 | — | — |
| Q2 2012 | 2011-12-31 | 0.93 | — | — |
| Q1 2012 | 2011-09-30 | 1.23 | — | — |
| Q4 2011 | 2011-06-30 | 1.55 | — | — |
Eloxx Pharmaceuticals current ratio trends
Over the last five fiscal years, Eloxx Pharmaceuticals's current ratio decreased from 2.63 to 0.31, a change of −2.33. The latest reported quarter, Q2 2026, shows 3.74.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...